Joincare subsidiary wins approval for single-dose flu treatment Pixavir Marboxil

Joincare Pharmaceutical Group Industry announced its subsidiary has received a drug registration certificate from the National Medical Products Administration for Pixavir Marboxil Capsules (Yilikang). This innovative Class 1 new drug is approved for the treatment of uncomplicated influenza A and B in otherwise healthy individuals aged 12 years and older. The approval is based on a Phase III study demonstrating clinical benefits in efficacy and safety.

Pixavir Marboxil Capsules offer significant clinical advantages, including a single-dose regimen that improves patient compliance. The drug effectively reduces flu symptom duration, with a 27-hour reduction in overall flu symptoms compared to placebo and a 31-hour reduction for influenza B patients. It also showed a 61-hour reduction in symptom duration for adolescent flu patients. The drug exhibits a low risk of drug resistance and a favorable safety profile with a low incidence of adverse reactions.

The total research and development investment for Pixavir Marboxil Capsules amounted to approximately CNY 20,303.61万元. The anti-influenza drug market in China was estimated at approximately CNY 47亿元 in 2024. The company cautioned investors about potential risks due to evolving industry policies, procurement tenders, and market dynamics.